Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Clinical manifestations and diagnosis of hemophilia

INTRODUCTION

The hemophilias are a group of related bleeding disorders that most commonly are inherited. Inherited bleeding disorders include abnormalities of coagulation factors and platelet function; the most common of these is von Willebrand disease. However, when the term "hemophilia" is used, it most often refers to the following two disorders:

Factor VIII deficiency (hemophilia A)

Factor IX deficiency (hemophilia B, Christmas disease)

The clinical manifestations and diagnosis of these conditions will be reviewed here. Therapy with replacement factors and the development of inhibitors are discussed separately. (See "Treatment of hemophilia" and "Factor VIII and factor IX inhibitors in patients with hemophilia".)

CLINICAL MANIFESTATIONS

Hemophilia A and B are X-linked recessive diseases. They exhibit a range of clinical severity that correlates well with assayed factor levels. Severe disease is defined as <1 percent factor activity, whereas 1 to 5 percent and >5 percent of normal are defined as moderate and mild disease, respectively [1,2]. Males within a family have the same level of deficiency because they share the same genetic defect.

                        

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jun 2014. | This topic last updated: Dec 12, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. White GC 2nd, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85:560.
  2. Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost 2010; 8:421.
  3. Walker I, Pai M, Akabutu J, et al. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion 1995; 35:548.
  4. Santagostino E, Mancuso ME, Tripodi A, et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010; 8:737.
  5. Crossley M, Ludwig M, Stowell KM, et al. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science 1992; 257:377.
  6. Reijnen MJ, Peerlinck K, Maasdam D, et al. Hemophilia B Leyden: substitution of thymine for guanine at position -21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoter. Blood 1993; 82:151.
  7. Kurachi S, Huo JS, Ameri A, et al. An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden. Proc Natl Acad Sci U S A 2009; 106:7921.
  8. Lee DH, Walker IR, Teitel J, et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost 2000; 83:387.
  9. Shetty S, Vora S, Kulkarni B, et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 2007; 138:541.
  10. van Dijk K, van der Bom JG, Fischer K, et al. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost 2004; 92:305.
  11. Escuriola Ettingshausen C, Halimeh S, Kurnik K, et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001; 85:218.
  12. Aviña-Zubieta JA, Galindo-Rodriguez G, Lavalle C. Rheumatic manifestations of hematologic disorders. Curr Opin Rheumatol 1998; 10:86.
  13. Venkateswaran L, Wilimas JA, Jones DJ, Nuss R. Mild hemophilia in children: prevalence, complications, and treatment. J Pediatr Hematol Oncol 1998; 20:32.
  14. Mauser Bunschoten EP, van Houwelingen JC, Sjamsoedin Visser EJ, et al. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost 1988; 59:349.
  15. Ljung R, Petrini P, Nilsson IM. Diagnostic symptoms of severe and moderate haemophilia A and B. A survey of 140 cases. Acta Paediatr Scand 1990; 79:196.
  16. Rizza CR. The clinical features of clotting factor deficiencies. In: Human Blood Coagulation Haemostasis and Thrombosis, 2nd ed, Biggs R (Ed), Blackwell Scientific Publications, Oxford 1976. p.238.
  17. Eyster ME, Gill FM, Blatt PM, et al. Central nervous system bleeding in hemophiliacs. Blood 1978; 51:1179.
  18. Klinge J, Auberger K, Auerswald G, et al. Prevalence and outcome of intracranial haemorrhage in haemophiliacs--a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH). Eur J Pediatr 1999; 158 Suppl 3:S162.
  19. Kulkarni R, Lusher JM. Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature. J Pediatr Hematol Oncol 1999; 21:289.
  20. Tarantino MD, Gupta SL, Brusky RM. The incidence and outcome of intracranial haemorrhage in newborns with haemophilia: analysis of the Nationwide Inpatient Sample database. Haemophilia 2007; 13:380.
  21. Richards M, Lavigne Lissalde G, Combescure C, et al. Neonatal bleeding in haemophilia: a European cohort study. Br J Haematol 2012; 156:374.
  22. Koch JA. Haemophilia in the newborn. A case report and literature review. S Afr Med J 1978; 53:721.
  23. Martinowitz U, Varon D, Jonas P, et al. Circumcision in hemophilia: the use of fibrin glue for local hemostasis. J Urol 1992; 148:855.
  24. Pollmann H, Richter H, Ringkamp H, Jürgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 158 Suppl 3:S166.
  25. Gilbert MS. Musculoskeletal manifestations of hemophilia. Mt Sinai J Med 1977; 44:339.
  26. Kitchens CS. Occult hemophilia. Johns Hopkins Med J 1980; 146:255.
  27. Plummer ES, Crary SE, Buchanan GR. Prominent forehead hematomas ("goose-eggs") as an initial manifestation of hemophilia. J Pediatr 2013; 163:1781.
  28. Nelson MD Jr, Maeder MA, Usner D, et al. Prevalence and incidence of intracranial haemorrhage in a population of children with haemophilia. The Hemophilia Growth and Development Study. Haemophilia 1999; 5:306.
  29. Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol 2008; 140:378.
  30. Witmer C, Presley R, Kulkarni R, et al. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol 2011; 152:211.
  31. Fernandez-Palazzi F, Hernandez SR, De Bosch NB, De Saez AR. Hematomas within the iliopsoas muscles in hemophilic patients: the Latin American experience. Clin Orthop Relat Res 1996; :19.
  32. Jaovisidha S, Ryu KN, Hodler J, et al. Hemophilic pseudotumor: spectrum of MR findings. Skeletal Radiol 1997; 26:468.
  33. Bogdan CJ, Strauss M, Ratnoff OD. Airway obstruction in hemophilia (factor VIII deficiency): a 28-year institutional review. Laryngoscope 1994; 104:789.
  34. Jones JJ, Kitchens CS. Spontaneous intra-abdominal hemorrhage in hemophilia. Arch Intern Med 1984; 144:297.
  35. McCoy HE 3rd, Kitchens CS. Small bowel hematoma in a hemophiliac as a cause of pseudoappendicitis: diagnosis by CT imaging. Am J Hematol 1991; 38:138.
  36. Small S, Rose PE, McMillan N, et al. Haemophilia and the kidney: assessment after 11-year follow-up. Br Med J (Clin Res Ed) 1982; 285:1609.
  37. Prentice CR, Lindsay RM, Barr RD, et al. Renal complications in haemophilia and Christmas disease. Q J Med 1971; 40:47.
  38. McDonald AG, Yang K, Roberts HR, et al. Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia. Blood 2008; 111:2046.
  39. Jansen NW, Roosendaal G, Lafeber FP. Understanding haemophilic arthropathy: an exploration of current open issues. Br J Haematol 2008; 143:632.
  40. Madhok R, Bennett D, Sturrock RD, Forbes CD. Mechanisms of joint damage in an experimental model of hemophilic arthritis. Arthritis Rheum 1988; 31:1148.
  41. Steven MM, Yogarajah S, Madhok R, et al. Haemophilic arthritis. Q J Med 1986; 58:181.
  42. Hakobyan N, Kazarian T, Jabbar AA, et al. Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene. Blood 2004; 104:2060.
  43. Ghosh K, Shankarkumar U, Shetty S, Mohanty D. Chronic synovitis and HLA B27 in patients with severe haemophilia. Lancet 2003; 361:933.
  44. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients--a long-term follow-up. J Intern Med 1997; 241:395.
  45. Petrini P, Lindvall N, Egberg N, Blombäck M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991; 13:280.
  46. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236:391.
  47. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357:535.
  48. Molho P, Rolland N, Lebrun T, et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophiles@cch.ap-hop-paris.fr. Haemophilia 2000; 6:23.
  49. Mannucci PM. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang 1993; 64:197.
  50. Troisi CL, Hollinger FB, Hoots WK, et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993; 81:412.
  51. Kumar A, Kulkarni R, Murray DL, et al. Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia. J Med Virol 1993; 41:205.
  52. Kroner BL, Rosenberg PS, Aledort LM, et al. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1994; 7:279.
  53. Soucie JM, Richardson LC, Evatt BL, et al. Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males. Transfusion 2001; 41:338.
  54. Arnold DM, Julian JA, Walker IR, Association of Hemophilia Clinic Directors of Canada. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood 2006; 108:460.
  55. Tradati F, Colombo M, Mannucci PM, et al. A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. Blood 1998; 91:1173.
  56. Eyster ME, Diamondstone LS, Lien JM, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6:602.
  57. Morfini M, Mannucci PM, Ciavarella N, et al. Prevalence of infection with the hepatitis C virus among Italian hemophiliacs before and after the introduction of virally inactivated clotting factor concentrates: a retrospective evaluation. Vox Sang 1994; 67:178.
  58. Horowitz B, Prince AM, Hamman J, Watklevicz C. Viral safety of solvent/detergent-treated blood products. Blood Coagul Fibrinolysis 1994; 5 Suppl 3:S21.
  59. Santagostino E, Mannucci PM, Gringeri A, et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion 1997; 37:517.
  60. Gaboulaud V, Parquet A, Tahiri C, et al. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. Br J Haematol 2002; 116:383.
  61. Morfini M, Longo G, Rossi Ferrini P, et al. Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: the role of human B19 parvovirus. Am J Hematol 1992; 39:149.
  62. Evatt B. Creutzfeldt-Jakob disease and hemophilia: Assessment of risk. World Federation of Hemophilia 1999; No 15.
  63. Donfield SM, Lynn HS, Lail AE, et al. Delays in maturation among adolescents with hemophilia and a history of inhibitors. Blood 2007; 110:3656.
  64. Rosendaal FR, Varekamp I, Smit C, et al. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989; 71:71.
  65. Rosendaal FR, Briët E, Stibbe J, et al. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990; 75:525.
  66. Srámek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003; 362:351.
  67. Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110:815.
  68. Foley CJ, Nichols L, Jeong K, et al. Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost 2010; 8:208.
  69. Thompson AR, Bajaj SP, Chen SH, MacGillivray RT. "Founder" effect in different families with haemophilia B mutation. Lancet 1990; 335:418.
  70. Lawn RM. The molecular genetics of hemophilia: blood clotting factors VIII and IX. Cell 1985; 42:405.
  71. MERSKEY C. The occurrence of haemophilia in the human female. Q J Med 1951; 20:299.
  72. Panarello C, Acquila M, Caprino D, et al. Concomitant Turner syndrome and hemophilia A in a female with an idic(X)(p11) heterozygous at locus DXS52. Cytogenet Cell Genet 1992; 59:241.
  73. Mori PG, Pasino M, Vadalà CR, et al. Haemophilia 'A' in a 46,X,i(Xq) female. Br J Haematol 1979; 43:143.
  74. Keeling DM, Sukhu K, Kemball-Cook G, et al. Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954-->Leu substitution in the factor VIII A3 domain. Br J Haematol 1999; 105:1123.
  75. Rudzki Z, Duncan EM, Casey GJ, et al. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 1996; 94:400.
  76. Kleinveld HA, Andersson NE, van Voorthuizen H, et al. Determination of coagulation factor VIII activity by a chromogenic substrate method on STA, an automated coagulation analyzer. Scand J Clin Lab Invest 1999; 59:335.
  77. Hellstern P, Miyashita C, Köhler M, et al. Measurement of factor VIII procoagulant antigen in normal subjects and in hemophilia A patients by an immunoradiometric assay and by an enzyme-linked immunosorbent assay. Haemostasis 1987; 17:173.
  78. Klein HG, Aledort LM, Bouma BN, et al. A co-operative study for the detection of the carrier state of classic hemophilia. N Engl J Med 1977; 296:959.
  79. Goodeve AC. Advances in carrier detection in haemophilia. Haemophilia 1998; 4:358.
  80. Kazazian HH Jr. The molecular basis of hemophilia A and the present status of carrier and antenatal diagnosis of the disease. Thromb Haemost 1993; 70:60.
  81. Poon MC, Chui DH, Patterson M, et al. Hemophilia B (Christmas disease) variants and carrier detection analyzed by DNA probes. J Clin Invest 1987; 79:1204.
  82. Antonarakis SE, Waber PG, Kittur SD, et al. Hemophilia A. Detection of molecular defects and of carriers by DNA analysis. N Engl J Med 1985; 313:842.
  83. Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 1993; 5:236.
  84. Antonarakis SE, Rossiter JP, Young M, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995; 86:2206.
  85. Jenkins PV, Collins PW, Goldman E, et al. Analysis of intron 22 inversions of the factor VIII gene in severe hemophilia A: implications for genetic counseling. Blood 1994; 84:2197.
  86. Cutler J, Chappell LC, Kyle P, Madan B. Third trimester amniocentesis for diagnosis of inherited bleeding disorders prior to delivery. Haemophilia 2013; 19:904.
  87. Ljung RC. Prenatal diagnosis of haemophilia. Baillieres Clin Haematol 1996; 9:243.
  88. Peake I. Molecular genetics and counselling in haemophilia. Thromb Haemost 1995; 74:40.
  89. Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, et al. Bleeding in carriers of hemophilia. Blood 2006; 108:52.
  90. Knobe KE, Ljung RC. Haemophilia B carrier detection by factor IX:C analysis; no impact of the type of mutation or severity of disorder. Haemophilia 1999; 5:238.